Open Access
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
Magdalena Winiarska1,Eliza Glodkowska-Mrowka1,Jacek Bil1,Jakub Golab1
Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F building, 02-097 Warsaw, Poland
DOI: 10.2741/3688 Volume 16 Issue 1, pp.277-306
Published: 01 January 2011
(This article belongs to the Special Issue Frontiers in molecular medicine)

Anti-CD20 monoclonal antibodies (mAbs) have become the mainstay in the treatment of non-Hodgkin's lymphomas and have shown significant activity in patients with B-cell chronic lymphocytic leukemia. Antitumor action of these antibodies results from triggering of indirect effector mechanisms of the immune system that include activation of complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), or phagocytosis. Moreover, some studies indicate direct influence of anti-CD20 mAbs on tumor cells that leads to induction of various types of cell death. Despite the wealth of data on the mechanisms of cytotoxicity that accumulated over the last two decades their relative contribution to the therapeutic outcome is still difficult to predict in individual patients. Elucidation of molecular mechanisms of anti-CD20 mAbs action is necessary to deliver their maximal activity in rationally designed combinations with other therapeutic approaches and to design next generation anti-CD20 mAb with improved ability to eliminate tumor cells.

Share and Cite
Magdalena Winiarska, Eliza Glodkowska-Mrowka, Jacek Bil, Jakub Golab. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Frontiers in Bioscience-Landmark. 2011. 16(1); 277-306.